-
-
-
-
-
-
-
Hims and Hers (HIMS) PT Raised to $39 at Barclays, 'Our Proprietary Data Points to Sharp Inflection'
-
-
-
-
-
-
-
Hims and Hers (HIMS) PT Raised to $23 at Truist Securities
-
-
-
-
-
-
-
BTIG on Hims and Hers (HIMS): 'will need to aggressively manage sales and marketing costs'
-
-
-
-
-
-
-
Hims & Hers Health, Inc. (HIMS) Misses Q1 EPS by 41c, Misses on Revenue; Offers FY26 Revenue Guidance
-
-
-
-
-
-
-
JPMorgan Starts Hims and Hers (HIMS) at Overweight
-
-
-
-
-
-
-
Leerink Partners on Hims and Hers (HIMS): FDA meeting to discuss peptide restrictions 'clear positive,' could fill growth hole
-
-
-
-
-
-
-
BofA on Hims and Hers (HIMS): '$149/month subscription fee is slightly higher than we initially expected'
-
430,222 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

